...
首页> 外文期刊>Thrombosis Research: An International Journal on Vascular Obstruction, Hemorrhage and Hemostasis >Antithrombotic effects of PAR1 and PAR4 antagonists evaluated under flow and static conditions
【24h】

Antithrombotic effects of PAR1 and PAR4 antagonists evaluated under flow and static conditions

机译:在流动和静态条件下评估PAR1和PAR4拮抗剂的抗血栓形成作用

获取原文
获取原文并翻译 | 示例

摘要

Introduction Thrombin-mediated activation of human platelets involves the G-protein-coupled protease-activated receptors PAR1 and PAR4. Inhibition of PAR1 and/or PAR4 is thought to modulate platelet activation and subsequent procoagulant reactions. However, the antithrombotic effects of PAR1 and PAR4 antagonism have not been fully elucidated, particularly under flow conditions. Materials and Methods A microchip-based flow chamber system was used to evaluate the influence of SCH79797 (PAR1 antagonist) and YD-3 (PAR4 antagonist) on thrombus formation mediated by collagen and tissue thromboplastin at shear rates simulating those experienced in small- to medium-sized arteries (600 s - 1) and large arteries and small veins (240 s- 1). Results At a shear rate of 600 s- 1, SCH79797 (10 μM) efficiently reduced fibrin-rich platelet thrombi and significantly delayed occlusion of the flow chamber capillary (1.44 fold of control; P 0.001). The inhibitory activity of SCH79797 was diminished at 240 s- 1. YD-3 (20 μM) had no significant effect at either shear rate. The antithrombotic effects of SCH79797 were significantly augmented when combined with aspirin and AR-C66096 (P2Y12 antagonist), but not with YD-3. In contrast, no significant inhibition of tissue factor-induced clot formation under static conditions was observed in blood treated with SCH79797 and YD-3, although thrombin generation in platelet-rich plasma was weakly delayed by these antagonists. Conclusions Our results suggest that the antithrombotic activities of PAR1 and/or PAR4 antagonism is influenced by shear conditions as well as by combined platelet inhibition with aspirin and a P2Y12-antagonist.
机译:简介凝血酶介导的人类血小板活化涉及G蛋白偶联的蛋白酶活化受体PAR1和PAR4。 PAR1和/或PAR4的抑制被认为可调节血小板活化和随后的促凝反应。但是,尚未充分阐明PAR1和PAR4拮抗作用的抗血栓形成作用,尤其是在流动条件下。材料和方法基于微芯片的流动室系统用于评估SCH79797(PAR1拮抗剂)和YD-3(PAR4拮抗剂)对胶原和组织促凝血酶原介导的血栓形成的影响,其剪切速率模拟了中小型细菌的剪切速率。大动脉(600 s-1)和大动脉和小静脉(240 s-1)。结果SCH79797(10μM)在600 s-1的剪切速率下有效降低了富含纤维蛋白的血小板血栓,并显着延迟了血流腔毛细管的阻塞(对照组的1.44倍; P <0.001)。 SCH79797的抑制活性在240 s-1时减弱。YD-3(20μM)在任一剪切速率下均无明显影响。当与阿司匹林和AR-C66096(P2Y12拮抗剂)联合使用时,SCH79797的抗血栓形成作用显着增强,而与YD-3组合则没有。相反,在静态条件下,用SCH79797和YD-3处理的血液中未观察到明显的组织因子诱导的血凝块形成抑制作用,尽管富血小板血浆中的凝血酶生成被这些拮抗剂微弱地延迟了。结论我们的结果表明,PAR1和/或PAR4拮抗作用的抗血栓形成活性受剪切条件以及阿司匹林和P2Y12拮抗药的联合血小板抑制作用的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号